Revelation Biosciences, Inc. Announces Key Shareholder Approvals and Potentially Dilutive Issuance of Common Stock

San Diego, CA – March 18, 2026 – Revelation Biosciences, Inc. (“the Company” or “Revelation Biosciences”) has released a significant update following its recent Special Meeting of Stockholders, which may have important implications for current and prospective investors.

Key Highlights from the 8-K Filing

• Shareholders Approve Potentially Dilutive Issuance of Common Stock: The Company’s shareholders have approved the reservation and issuance of shares of common stock in connection with the Class J Common Stock Warrants. This approval allows Revelation Biosciences to issue shares that could exceed 20% of its total outstanding shares — a threshold known as the “Exchange Cap” under Nasdaq rules.
• Material Modification to Rights of Security Holders: The approval to issue shares above the Exchange Cap represents a material modification to the rights of existing security holders, as it enables the Company to issue a substantial number of new shares at prices potentially below market value. This could lead to significant dilution for current shareholders and may impact the market price of the Company’s stock.
• Warrants Details: The Class J Common Stock Warrants, dated January 26, 2026, were issued to certain purchasers as part of a warrant inducement letter dated January 23, 2026. Each warrant is exercisable for a portion of a common share at terms that could trigger dilution if exercised in large volumes.
• Shareholder Approval for Adjournment: Stockholders also approved the discretionary authority to adjourn the Special Meeting if there were insufficient proxies to approve the issuance of shares beyond the Exchange Cap. No broker non-votes were recorded for this proposal.

What Investors Need to Know

• Potential for Significant Dilution: The ability to issue shares above the Exchange Cap means that, should the warrants be exercised, the number of outstanding shares could increase considerably. This would dilute the value of existing shares and may put downward pressure on the stock price.
• Price Sensitivity: Issuing shares below the prevailing market price, particularly in an amount exceeding 20% of outstanding shares, is generally viewed as a negative by markets due to its dilutive effect. This is a material event and may impact investor sentiment and share value in the short term.
• Regulatory Compliance: The Company’s actions are compliant with Nasdaq rules, provided shareholder approval is obtained for issuances exceeding the Exchange Cap, which has now been granted.
• No Change in Emerging Growth Company Status: Revelation Biosciences has indicated it is not an emerging growth company and has not elected to use any extended transition period for complying with new or revised financial accounting standards.
• Security Listing: The Company’s common stock (trading symbol: REVB) and redeemable warrants (trading symbol: REVBW) remain listed on The Nasdaq Stock Market LLC.

Summary Table of Securities

Materiality and Price Sensitivity

The approval to issue shares in excess of the Exchange Cap is a material event that shareholders and potential investors should carefully consider. Such actions are likely to impact the Company’s capital structure, may influence the trading price of the Company’s securities, and could result in significant dilution for existing shareholders.

Next Steps

The Company will proceed with the reservation and potential issuance of shares as authorized. Investors are encouraged to review the definitive proxy statement filed on February 17, 2026, for additional details regarding the terms of the warrants and associated agreements.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should perform their own due diligence and consult with a financial advisor before making any investment decisions. The author and publisher are not responsible for any losses arising from reliance on the information provided herein.

View REVELATION BIOSCIENCES, INC. Historical chart here